Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220689
| (in thousands, except share and per share amounts) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $17,595 | $26,701 |
| General and administrative | 17,565 | 6,590 |
| Total operating expenses | $35,160 | $33,291 |
| Loss from operations | (35,160) | (33,291) |
| Other income (expense): | ||
| Interest income | 3,935 | 805 |
| Change in fair value of warrant liabilities | (188,360) | — |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Vor Biopharma's G&A?
- Vor Biopharma (VOR) reported G&A of $17.57M in Q1 2026.
- How has Vor Biopharma's G&A changed year-over-year?
- Vor Biopharma's G&A increased by 166.5% year-over-year, from $6.59M to $17.57M.
- What is the long-term trend for Vor Biopharma's G&A?
- Over 4 years (2021 to 2025), Vor Biopharma's G&A has grown at a 23.6% compound annual growth rate (CAGR), from $21.49M to $50.11M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Vor Biopharma's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude